Despite being expressed in various immune cell types, CTLs present a predominant expression level of CD8A (Ma K. et al., 2020), which could be a direct indication of pre-existing antitumor immunity with tumor-infiltrating CTLs in TME (Lei et al., 2021). Here, CD8A is linked to neoplasm.